NURIX THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
NURIX THERAPEUTICS, INC. (NRIX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $104.20 million for the 12-month period ending 2025-11-30, per its 10-K filed 2026-01-28.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-01-28
- NURIX THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $104.20M, a 212.91% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $33.30M, a 39.89% decline from fiscal 2023.
- NURIX THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $55.40M, a 1.09% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $54.80M, a 51.80% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-11-30 | $104.20M 10-K · filed 2026-01-28 |
| 2024-11-30 | $33.30M 10-K · filed 2026-01-28 |
| 2023-11-30 | $55.40M 10-K · filed 2025-01-28 |
| 2022-11-30 | $54.80M 10-K · filed 2024-02-15 |
| 2021-11-30 | $36.10M 10-K · filed 2023-02-09 |
| 2020-11-30 | $7.60M 10-K · filed 2022-01-28 |
| 2019-11-30 | $8.50M 10-K · filed 2022-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |